anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study is to assess the effects of REMICADE (infliximab) in preventing relapse of Crohn's disease after surgical resection. Patients will be assigned to a group that will initially receive either infliximab or placebo. Each patient who is allowed to join the study is put into a group by chance (randomly), like flipping a coin. There is a possibility that patients can receive both the study drug and placebo at different times in the study. If a patient is initially randomized to receive placebo, and their study doctor confirms that they have had a return of active Crohn's Disease symptoms, they can receive infliximab. If a patient is initially randomized to receive infliximab, and their study doctor confirms that they are experiencing symptoms of Crohn's Disease, they may receive an increase in their infliximab dose. Infusions will be administered at Week 0 and then every 8 weeks thereafter through Week 200. The study will use a measure of Crohn's Disease activity that will be evaluated at each visit and at any time the patient has symptoms suggestive of their disease getting worse in order to capture recurrence. During the study, patients who meet the study definition of clinical recurrence will be eligible to have a blinded infliximab dose increase of 5 mg/kg. In other words, patients receiving placebo would receive infliximab 5 mg/kg, and patients receiving infliximab 5 mg/kg would have a dose increase to 10 mg/kg. Approximately 175 sites will be utilized, and approximately 290 patients will be enrolled. The interval between the first and last dose of study agent is 200 weeks. The planned duration of study participation is a maximum of 209 weeks (with a 1-week screening period, a 200-week treatment period, and a final study visit at Week 208). Group I (infliximab infusions): infliximab (5 mg/kg) will be administered by intravenous (IV) infusion at Week 0 and every 8 weeks thereafter through Week 200. Group II (placebo infusions): placebo will be administered by IV infusion at Week 0 and every 8 weeks thereafter through Week 200
Exome and genome sequencing (ES/GS) are routinely used for the diagnosis of genetic diseases in developed countries. However, their implementation is limited in countries from Latin America. We aimed to describe the results of GS in patients with suspected rare genetic diseases in Colombia. We studied 501 patients from 22 healthcare sites from January to December 2022. GS was performed in the index cases using dried blood spots on filtercards. Ancestry analysis was performed under iAdmix. Multiomic testing was performed when needed (biomarker, enzymatic activity, RNA-seq). All tests were performed at an accredited genetic laboratory. Ethnicity prediction data confirmed that 401 patients (80%) were mainly of Amerindian origin. A genetic diagnosis was established for 142 patients with a 28.3% diagnostic yield. The highest diagnostic yield was achieved for pathologies with a metabolic component and syndromic disorders (p < 0.001). Young children had a median of 1 year of diagnostic odyssey, while the median time for adults was significantly longer (15 years). Patients with genetic syndromes have spent more than 75% of their life without a diagnosis, while for patients with neurologic and neuromuscular diseases, the time of the diagnostic odyssey tended to decrease with age. Previous testing, specifically karyotyping or chromosomal microarray were significantly associated with a longer time to reach a definitive diagnosis (p < 0.01). Furthermore, one out of five patients that had an ES before could be diagnosed by GS. The Colombian genome project is the first Latin American study reporting the experience of systematic use of diagnostic GS in rare diseases.
Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
The focus of this article, within this BBI horizons special issue, is on sex, gender, and pain. We summarise what is currently known about sex- and gender-related variations in pain, exploring intersectional biological and psychosocial mechanisms, and highlight gaps in knowledge and understanding. Five key challenges with the exploration of sex and gender in pain research are presented, relating to: conceptual imprecision, research bias, limitations with binary descriptions, integrating sex and gender, and timely adoption/implementation of good research practice. Guidance on how to overcome such challenges is provided. Despite clear evidence for sex and gender differences in pain, there are conceptual and methodological barriers to overcome. Innovation in methods and approach can help develop more effective and tailored treatment approaches for men, women, boys, girls, and gender-diverse people.
The present invention discloses injected bone morphogenetic protein using fibrin as carriers, which is suitable for clinically treating fractures, nonunion and bone defect. Fibrin separated from patients' blood or healthy blood donors' blood is used as carriers, compounded cow bone morphogenetic protein is directly injected to the local injury part percutaneously to perform the functions of slow release of the carriers, and new bone growth promotion, fracture union and wound repair acceleration of the bone morphogenetic protein. The present invention does not result in immunogenicity or rejection reaction, and has no adverse reaction after implanted in the body. Before used, the fibrin is liquid, can be rapidly solidified in the body, and can be shaped randomly. In addition, the functions of hemostasis and cementation of the fibrin are favourable for preventing and curing local hematoma, which provides a favorable local environment for the regeneration and the union of bones. Animal experiments and clinical tests prove that the present invention has exact treatment effect, wide range of application, easy operation, safety and reliability.
Patients receive 21 tablets of 4 mg methylprednisolone to be taken by mouth over a 6 week taper. Patients will be advised to not take other anti-inflammatory medications like NSAIDs.
Certain embodiments of the present invention provide improved clinical workflow using a medical imaging and information management system and method with enhanced communication capabilities. Certain embodiments of the system include an information manager including clinical content, such as images and/or information, and a communication manager receiving an event notification from the information manager. The system may further include an interface capable of accessing the information manager. Additionally, the system may include a contact device capable of communicating via the communication manager. A modality may transmit examination data to the information manager and may receive instructions for the information manager. In an embodiment, the communications manager includes a contact information list with one or more contact devices associated with a user. The communications manager may be capable of detecting a presence of a user on a network.
The present application relates to compounds, and uses thereof for example for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a viral infection or disease. In an embodiment, the virus is a respiratory virus, and the viral disease is a viral respiratory disease. In embodiments, the viral infection is a SARS or respiratory syncytial virus (RSV) infection. In embodiments, the viral infection is a SARS infection, e.g., a SARS-CoV-2 infection. In embodiments, the disease is COVID-19. In embodiments the compounds may also be used for inhibiting a viral nucleic acid polymerase, e.g., a viral RNA-dependent RNA polymerase (RdRp). In embodiments, the compound is a compound of Formula I, Formula II or Formula III, or a pharmaceutically acceptable salt, prodrug, N-oxide or solvate thereof.
This is the same as the sitting condition, but participants will be asked to break their sitting time by standing close to their chair for 5 minutes, after 15 and 45 minutes of each hour following breakfast. The standing protocol will be repeated after lunch. Individuals will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
An anhydrous alcohol gel formulation. The gel formulation comprises one or more film forming agents, one of which is TM-Si 5. The gel formulation comprises active agent(s), which differs based on the purpose of the gel formulation. In certain embodiments, the gel formulation comprises one or more emollients. In certain embodiments, the gel formulation comprises one or more viscosity increasing agents. In certain embodiments, the gel formulation comprises Zinc Oxide. The formulation optionally comprises other ingredients. Such optional ingredients include: a skin conditioning and/or bulking agent; a fragrance, such as, for example and without limitation, Fragrance SZ-2108 MOD 2010; etc.
The Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. Seraph 100 is an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. It is intended for use with standard, commercially available bloodlines compatible with the pump system used. Female Luer connectors are required to connect to the Seraph 100 blood ports.
The principal function of skin is to form an effective barrier between the human body and its environment. Impaired barrier function represents a precondition for the development of skin diseases such as atopic dermatitis (AD), which is the most common inflammatory skin disease characterized by skin barrier dysfunction. AD significantly affects patients' quality of life, thus, there is a growing interest in the development of novel delivery systems that would improve therapeutic outcomes. Herein, eight novel lyotropic liquid crystals (LCCs) were investigated for the first time in a double-blind, interventional, before-after, single-group trial with healthy adult subjects and a twice-daily application regimen. LCCs consisted of constituents with skin regenerative properties and exhibited lamellar micro-structure, especially suitable for dermal application. The short- and long-term effects of LCCs on TEWL, SC hydration, erythema index, melanin index, and tolerability were determined and compared with baseline. LCCs with the highest oil content and lecithin/Tween 80 mixture stood out by providing a remarkable 2-fold reduction in TEWL values and showing the most distinctive decrease in skin erythema levels in both the short- and long-term exposure. Therefore, they exhibit great potential for clinical use as novel delivery systems for AD treatment, capable of repairing skin barrier function.
The burden of childhood visual impairment and disparities in access to pediatric vision care remain pressing issues in the United States. School-based vision programs (SBVPs) serve as one approach to advancing health equity. Operating at the intersection of schools and healthcare, SBVPs can increase access to pediatric vision services, improve academic performance, and facilitate referrals to community vision care providers. To maximize their impact, SBVPs must tailor their services to the individual needs and resources of local school communities. School nurses, who have strong ties to school health care services and the school community, are trusted partners in building SBVPs. This article aims to facilitate SBVP development, implementation, and sustainability processes by offering guidance for school nurses and other stakeholders who aim to build a SBVP, support local programs, or learn more about how SBVPs operate.
In certain embodiments, the invention comprises the use of plant-derived substances to reduce body fat and/or to increase insulin sensitivity in mammals. In certain embodiments, the invention comprises a composition for reducing the amount of fat in the body of a mammal, the composition comprising at least one plant-derived substance which inhibits adipogenesis in the body of the mammal and at least one plant-derived substance which promotes lipolysis in the body of the mammal. In certain embodiments, the invention comprises a composition for reducing the amount of fat in the body of a mammal, the composition comprising at least one plant-derived substance which inhibits adipogenesis in the body of the mammal, at least one plant-derived substance which promotes lipolysis in the body of the mammal, and at least one plant-derived substance which inhibits lipogenesis in the body of the mammal. In certain embodiments, capsaicin may be used in combination with other plant-derived substances to reduce the body fat in a mammalian subject. In one embodiment, an effective amount of a composition comprising capsaicin in combination with grape seed extract and/or genistein and/or caffeine may be administered to a subject to reduce the body fat of the subject. In one embodiment, a composition comprising grape seed extract is administered to a mammalian subject to increase insulin sensitivity.
FIELD: medicine. ^ SUBSTANCE: way of reception of a ceramic biodegraded material on the basis of renanite, including charge preparation, containing sodium salt and calcium phosphate, formation, baking is described. As sodium salt the charge contains sodium chloride, and as calcium phosphate -calcium hydroxyapatite. The charge is prepared using interaction of aqueous solutions of calcium chloride and sodium hydrophosphate in alkaline medium. The structure of initial charge - 65-80% of calciun hydroxyapatite and 20-35% of sodium chloride is caused by adsorption of an accompanying product of reaction at synthesis of hydroxyapatite nanopowder. ^ EFFECT: uniform distribution of components provides formation of a ceramic biodegraded material on a basis of renanite in the range of temperatures 800-1200C within 2-6 hours. ^ 2 cl, 1 tbl, 1 ex
FIRVANQ for oral administration contains the hydrochloride salt of vancomycin, a tricyclic glycopeptide antibiotic derived from Amycolatopsis orientalis(formerly Nocardia orientalis), which has the chemical formula C 66H 75Cl 2N 9O 24•HCl. The molecular weight of vancomycin hydrochloride is 1485.71 g/mol. 

Vancomycin hydrochloride has the structural formula:

Each FIRVANQ kit contains a bottle of vancomycin hydrochloride USP, as white to almost white or tan to brown powder for oral solution, and a bottle of pre‑measured Grape‑Flavored Diluent, in the strengths and volumes listed in Table 3. 

The Grape‑Flavored Diluent used to reconstitute the oral solution contains: artificial grape flavor, citric acid (anhydrous), D&C Yellow No. 10, FD&C Red No. 40, purified water, sodium benzoate and sucralose.
PURPOSE: Perifoveal exudative vascular anomalous complex is an uncommon retinal lesion of idiopathic origin characteristically described as an isolated, aneurysmal lesion of the perifoveal region. We report an unusual presentation of an exudative vascular anomalous complex-like lesion affecting the peripapillary area.
CASE DESCRIPTION: A 69-year-old diabetic woman presented with blurred vision in her left eye for two months. Fundus examination of the left eye showed a small, reddish-orange lesion just supratemporal to the optic disc with perifoveal hard exudates and retinal thickening. Fundus fluorescein angiography demonstrated a peripapillary hyperfluorescent lesion with minimal leakage. Ocular coherence tomography showed an oval structure extending throughout the outer and inner plexiform and nuclear layers with a hyper-reflective wall accompanied by subfoveal and intraretinal fluid suggestive of an eVAC-like lesion in the peripapillary area. Intravitreal anti-vascular endothelial growth factor injection was given, and the lesion persisted even three weeks after the injection. Later, focal laser photocoagulation of the aneurysmal lesion was done. At 6 weeks follow-up, a complete resolution of the aneurysmal lesion with a marked decrease in retinal edema and an improvement of the visual acuity was observed.
CONCLUSION: Exudative intraretinal aneurysmal lesions can occur in areas other than perifoveal area. OCT is an useful investigation for knowing their characteristics and the response to treatment. These aneurysmal lesions irrespective of their location can be called by the name eVAC-like or more aptly retinal capillary macro aneurysms (RCM).
OBJECTIVE: Children born preterm, especially those born very preterm (<32 weeks of gestational age [GA]) are at risk for poor growth and adverse neurodevelopmental outcomes. Adverse growth and neurodevelopmental outcomes in preterm children have been attributed, in part, to the aversive sounds and relative speech paucity of the neonatal intensive care unit (NICU). Experimental studies that directly expose preterm infants to speech sounds in the NICU find significant improvements in health factors relevant to neurodevelopment. Few studies have examined whether natural variations in the speech environment of the NICU are related to short-term health outcomes in preterm infants. Such data are important for optimizing the sound environment of the NICU. Our objective was to examine relations between the NICU speech environment and the rate of weight gain during hospitalization.
STUDY DESIGN: Participants were infants born very preterm (n = 20). The speech environment of each infant was assessed at 32 to 36 weeks of postmenstrual age using an automatic speech-counting device. Average rates of weight gain (g/kg/d) were ascertained over the same period. Calories were derived from charted intake (kcals/kg/d). Linear regressions examined caloric intake and speech counts as predictors of infant weight gain.
RESULTS: Infant weight gain was significantly predicted by caloric intake and speech exposure, each uniquely accounting for approximately 27% variance (total R 2 = 60.2%; p < 0.001). Speech counts were uncorrelated with rates of family visitation, time in incubator, or health acuity.
CONCLUSION: While future research should establish causality and direction of effects, enhancing speech exposure in the NICU may be beneficial for physical growth. NICU care plans should consider opportunities to increase speech exposure.
KEY POINTS: · Preterm infants who experienced greater amounts of speech in the NICU gained significantly more weight than preterm infants who were exposed to lower amounts of speech during the same developmental period (32-36 weeks of postmenstrual age).. · Caloric intake and speech counts accounted for almost 60% of variance in infant weight gain between 32 and 36 weeks of postmenstrual age.. · Speech counts were not significantly correlated with family visitation, how long infants resided in incubators, or health acuity.. · Findings suggest that the NICU speech environment may play an important role in the physical health of preterm infants; however, more studies are needed to determine the directionality of the observed associations..
The invention discloses a traditional Chinese medicinal preparation for treating hemorrhoids. The traditional Chinese medicinal preparation is prepared from the following crude medicines in parts by weight: 20-25 parts of motherwort, 30-35 parts of hairyvein agrimony, 5-10 parts of phyla nodiflora, 10-15 parts of folium artemisiae argyi, 5-10 parts of liquorice root and 20-30 parts of verbena officinalis. Furthermore, the invention also discloses a preparation method. The traditional Chinese medicinal preparation is taken by one dosage every day, each dosage is decocted twice, and the turn of five days is taken as a treatment course. The herbal medicines adopted by the invention have functions of clearing away heat and toxic materials, stopping bleeding and removing swelling, and the preparation can be used for treating both symptoms and root causes and is free from side effect; for the patients of hemorrhoids, the preparation can be used for regulating disequilibrium and treating diseases, and can be used for rapidly and radically treating hemorrhoids in a mode of oral administration; and therefore, the preparation is good in curative effect on hemorrhoids, rapid to take effect and not easy in recurrence. The effective rate of the preparation on treating hemorrhoids is 100%.
A total of 120 subjects are planned to be recruited and divided into 4 groups according to age and intervention, including 30 in the juvenile intervention group, 30 in the juvenile control group, 30 in the adult intervention group and 30 in the adult control group. Two intervention groups received 650nm low-energy red light irradiation treatment with a 650nm low-energy light emitter, twice a day for 3 minutes each time, The subjects were treated and followed up for 3 months. The control group was not treated and followed up for 3 months too. All subjects were followed up before treatment, at the end of the 1st month and at the end of 3rd month. Angio-oct was used as the main examination to observe and record the vascular density and blood perfusion in macular area. Axial length, diopter and OCT were used as secondary observation indexes. At the end of the experiment, the data of the intervention group and the control group were compared
A method of synthesizing R1, R2-substituted-4′ (ax. or eq.)-OH anthracyclines and their corresponding salts of Formula (1) from daunorubicin or N-Trifluoroacetyl-4-R1-derivatives of daunorubicin, wherein R1 is defined as H, OH, and 4′-HO is defined as ax[ial]. The method includes producing N-Trifluoroacetyl daunorubicin and treating the N-Trifluoroacetyldaunorubicin or N-Trifluoroacetyl-4-R 1 -derivatives of daunorubicin, wherein R 1  is defined as H, OH, with dimethylsulfoxide activated by different acylating agents. The attained intermediate product is then treated with a strong base (ex. tertiary amines) resulting in the 4′-keto-N-Trifluoroacetyl-4-R 1  daunorubicin wherein R 1  is defined as H, OH, OMe. The 4′-keto-N-Trifluoroacetyl-4-R 1 -daunorubicin is reacted with a reducing agent, a derivative of a borohydride of an alkaline metal MHBL 3  , to produce N-Trifluoroacetyl-4′-epi-4-R 1 -daunorubicin. The N-Trifluoroacetyl-4′-epi-4-R 1 -daunorubicin undergoes hydrolysis in a basic solution to produce a derivate of an anthoacyclin which is halogenized [by complex halogenides] to form a 14-Hal-derivative. This result is then hydrolyzed by well-known methods in the presence of a formate of an alkaline metal to form the desired final compound.
Suicidal ideation and behavior, including four completed suicides, occurred in subjects treated with SILIQ in the psoriasis clinical trials. There were no completed suicides in the 12-week placebo-controlled portion of the trials. SILIQ users with a history of suicidality or depression had an increased incidence of suicidal ideation and behavior as compared to users without such a history [see Adverse Reactions ( 6.1)]. A causal association between treatment with SILIQ and increased risk of suicidal ideation and behavior has not been established. 

Prescribers should weigh the potential risks and benefits before using SILIQ in patients with a history of depression or suicidality. Patients with new or worsening symptoms of depression or suicidality should be referred to a mental health professional, as appropriate. Advise patients and caregivers to seek medical attention for manifestations of suicidal ideation and behavior, new onset or worsening depression, anxiety, or other mood changes. Prescribers should also re-evaluate the risks and benefits of continuing treatment with SILIQ if such events occur.

Because of the observed suicidal ideation and behavior in subjects treated with SILIQ, if an adequate response to SILIQ has not been achieved within 12 to 16 weeks, consider discontinuing therapy.

SILIQ is available only through a restricted program under a REMS [ see Warnings and Precautions ( 5.2)].